Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics reported changes to its board of directors. On January 6, 2026, the board appointed Scott Garland as a Class I director, with his term running until the 2027 annual meeting of stockholders, and named him Chair of the Nominating and Corporate Governance Committee effective January 7, 2026.
Garland previously consulted for the company from January 2024 until his appointment, receiving $314,650 and vesting in stock options to purchase 26,580 shares of common stock. As an outside director, he will receive annual cash compensation of $40,000 for board service and $10,000 for chairing the nominating committee, plus new stock options with a grant date fair value of about $650,000 that vest monthly over three years and fully vest upon a Change in Control. The company also entered into its standard indemnification agreement with him.
On the same day, Andrew Phillips, Ph.D. informed the board that he is resigning from the board, the Audit Committee, and the Nominating Committee effective January 7, 2026. His resignation is stated not to result from any disagreement regarding the company’s operations, policies, or practices.
Enliven Therapeutics, Inc. filed a registration statement to register 875,000 shares of its Common Stock reserved for issuance under the company’s 2025 Inducement Equity Incentive Plan. This plan is intended to grant equity awards to eligible individuals as an inducement to join or remain with the company. The filing also incorporates by reference Enliven’s previously filed annual, quarterly, and current reports, and describes standard Delaware law and company provisions for indemnifying directors and officers, including related insurance and indemnification agreements.
Enliven Therapeutics, Inc. reported that an individual serving as its President, CEO and Director has no beneficial ownership of the company’s securities as of 12/11/2025. Filed pursuant to Section 16(a) of the Exchange Act, the report indicates that this person does not hold any non-derivative or derivative securities of Enliven Therapeutics despite their leadership and board roles.
Enliven Therapeutics, Inc. appointed Richard Fair as President and Chief Executive Officer and a member of the board, effective December 11, 2025, while former CEO Samuel Kintz transitions to Head of Pipeline. Fair brings more than 25 years of product development and commercialization experience from Bellicum Pharmaceuticals, Roche/Genentech, and Johnson & Johnson.
Fair entered into an employment offer letter and a change in control and severance agreement that provide cash severance, bonus eligibility, extended option exercise periods, COBRA premium payments and full vesting of unvested equity awards if he is terminated without cause or resigns for Good Reason, with enhanced benefits in connection with a change in control. The board also adopted the 2025 Inducement Equity Incentive Plan, reserving 875,000 shares of common stock for equity awards to new hires under Nasdaq’s inducement and acquisition exceptions.
Enliven Therapeutics, Inc. (ELVN) disclosed that its Chief Scientific Officer filed a Form 4 reporting planned stock sales. On 11/19/2025, indirect holdings of common stock sold 12,008 shares at a weighted average price of $22.3013 and 492 shares at a weighted average price of $23.091, both coded as open market sales. These transactions were made under a Rule 10b5-1 trading plan adopted on November 15, 2024, which pre-schedules trades. After these sales, the reporting person’s trust beneficially owned 902,688 shares of Enliven common stock held through The Lyssikatos Revocable Trust 12/15/2011, where the officer serves as trustee.
Enliven Therapeutics, Inc. (ELVN) President, CEO and Director reported a sale of company stock in a Form 4 filing. On 11/17/2025, the reporting person sold 12,500 shares of common stock at a weighted average price of $21.8191, with individual trade prices ranging from $21.37 to $22.3537. The transaction is marked as a sale and was executed under a Rule 10b5-1 trading plan that was adopted on November 15, 2024, which is a pre-arranged plan designed to systematically sell shares over time. After this transaction, the reporting person indirectly beneficially owns 890,392 shares, held by The Kintz & Egan Trust Dated March 30, 2019, where the reporting person serves as trustee.
Enliven Therapeutics (ELVN) filed an 8‑K/A to amend its November 12, 2025 current report, correcting the press release attached as Exhibit 99.1.
The corrected release covers financial results for the quarter ended September 30, 2025. Information in Items 2.02 and 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act.
Enliven Therapeutics (ELVN) disclosed insider transactions by its Chief Operating Officer. On 11/07/2025, the reporting person executed sales of 6,054 shares at a weighted average price of $17.3503 and 613 shares at a weighted average price of $17.9371, effected under a Rule 10b5-1 trading plan adopted on September 30, 2024.
The trades were completed in multiple transactions within disclosed price ranges, and the shares are held indirectly by The Patel / Dong Family Trust, for which the reporting person serves as trustee. Following the reported sales, beneficial ownership stood at 269,974 shares held indirectly.
Enliven Therapeutics (ELVN) reported Q3 2025 results. Operating expenses were $25.1 million, driven by research and development of $18.2 million and general and administrative of $6.9 million. The company recorded a net loss of $20.1 million, or $0.32 per share, compared with a net loss of $23.2 million a year ago.
Cash, cash equivalents and marketable securities totaled $477.6 million as of September 30, 2025, supported by a June underwritten public offering of 9,920,987 shares and pre-funded warrants to purchase 1,780,263 shares, delivering $230.0 million gross proceeds. Net cash used in operating activities for the nine months was $54.5 million. Shares outstanding were 59,347,317 as of October 31, 2025.
The company filed an automatic shelf on August 13, 2025 and added an at-the-market program covering up to $200.0 million of common stock; no sales occurred under the program during the period. Management states existing liquidity will fund planned operating expenses and capital requirements for at least 12 months from issuance.
Enliven Therapeutics (ELVN) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and was issued on November 12, 2025.
The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated.